Search Results
Your search for The A,The A matches 32367 pages
Showing 26801 - 26850Newly Updated: Cancer Survivorship
This latest ASCO Answers guide helps patients transition into life after active treatment has finished. In addition to information on the challenges survivors may face and the importance of follow-up care, it includes a blank treatment summary and survivorship care form that patients can fill out...
Yanyan Lou, MD, PhD, Receives Inaugural 2014 Young Investigator Award Supported by the Women Who Conquer Cancer Campaign
Yanyan Lou, MD, PhD, a hematology/oncology fellow at The University of Texas MD Anderson Cancer Center, is the recipient of the very first 2014 Conquer Cancer Foundation of ASCO Young Investigator Award (YIA), generously supported by the Women Who Conquer Cancer. After receiving her medical degree...
2014 Breast Cancer Symposium to Focus on Collaborative Learning
ASCO’s educational symposia have historically provided attendees with a forum for learning and discussion, demonstrating ASCO’s commitment to promoting a network of global oncology expertise. The 2014 Breast Cancer Symposium, to be held in San Francisco from Thursday, September 4, to Saturday,...
Panitumumab Plus FOLFOX for KRAS Wild-Type Metastatic Colorectal Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Panitumumab (Vectibix) was recently approved by the U.S. Food and...
ASCO Guideline for Management of Brain Metastases From HER2-Positive Breast Cancer: An Important Framework
Brain metastases are a devastating complication of cancer, and occur in up to 50% of patients with advanced human epidermal growth factor 2 (HER2)-positive breast cancer. Management of brain metastases requires individualized coordination between the traditional treatment modalities for...
ASCO Clinical Practice Guideline: Disease Management in Advanced HER2-Positive Breast Cancer With Brain Metastases
As many as half of all patients with metastatic HER2-positive breast cancer develop brain metastases over time. The American Society of Clinical Oncology recently released a clinical practice guideline on disease management for patients with advanced HER2-positive breast cancer and brain...
Ado-Trastuzumab Emtansine as a Late Treatment for HER2-Positive Metastatic Breast Cancer—Better and Less Toxic Than Physician’s Choice
TH3RESA is a randomized phase III open-label study, reported in The Lancet Oncology and summarized in this issue of The ASCO Post, which examined the activity of ado-trastuzumab emtansine (Kadcyla) in heavily pretreated HER2-positive metastatic breast cancer.1 Formerly known as T-DM1,...
Ado-Trastuzumab Emtansine Improves Progression-Free Survival vs Physician’s Choice in Advanced HER2-Positive Breast Cancer
There are few treatment options for breast cancer patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic disease. In the open-label phase III TH3RESA trial reported in The Lancet Oncology by Ian E. Krop, MD, PhD, of the Dana-Farber Cancer Institute,...
James R. Downing, MD, Named CEO of St. Jude Children’s Research Hospital
St. Jude Children’s Research Hospital has announced the appointment of James R. Downing, MD, as its new Chief Executive Officer, effective July 15, 2014. Dr. Downing most recently has served as the Deputy Director, Executive Vice President and Scientific Director of the hospital. Dr. Downing’s...
Raja Flores, MD, Named Chair of New Thoracic Surgery Department at Mount Sinai
The Mount Sinai Health System has announced the creation of a new academic Department of Thoracic Surgery at the Icahn School of Medicine at Mount Sinai in New York. Raja M. Flores, MD, will be the Founding Chairman of the Department for the Mount Sinai Health System. Dr. Flores, the Steven and...
American Association for the Advancement of Science Cancer Research Award
The American Association for the Advancement of Science (AAAS) has named Li Ma, PhD, of The University of Texas MD Anderson Cancer Center, and Jeffrey Tyner, PhD, of Oregon Health & Science University, co-winners of the distinguished Martin and Rose Wachtel Cancer Research Award. Dr. Ma is...
National Institutes of Health Names New Council Members
The National Institutes of Health has announced the appointment of nine individuals to the NIH Council of Councils. The Council was established to advise the NIH Director on policies and activities of the Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), including...
Navigating Cancer in the Era of Personalized Medicine: Rev 2014 Explores Emerging Issues, Ideas for Action
Diagnosed with stage IV non–small cell lung cancer in 2011, Stephen Wright turned to patient support groups where he learned about the anaplastic lymphoma kinase (ALK) mutation and a new drug that targeted it, crizotinib (Xalkori). He asked—then insisted—that he be tested for the mutation. He found ...
FDA Advisory Committee Votes Against Accelerated Approval for Olaparib in Ovarian Cancer
The U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have...
Expert Point of View: Jeffrey S. Weber, MD, PhD
Jeffrey S. Weber, MD, PhD, Director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center and Research Institute, Tampa, Florida, was very impressed by the response rate and survival outcomes. “Responses were outstanding. Eight of nine patients in cohort 2...
Concurrent Immunotherapy Pays Off in Advanced Melanoma
In advanced melanoma, two immune checkpoint inhibitors may be better than one, according to the promising outcomes of a study reported at the 2014 ASCO Annual Meeting. Concurrent treatment with the anti–CTLA-4 antibody ipilimumab (Yervoy) and nivolumab, an antibody targeting the programmed death...
Expert Point of View: Nathan Fowler, MD
The ASCO Post asked for comment about the presentation by Nowakowski et al from Nathan Fowler, MD, who developed and led many of the early studies of R-Squared (lenalidomide [Revlimid], rituximab [Rituxan]), in lymphoma as well. Dr. Fowler is Associate Professor in the Department of...
‘R-Squared’ Regimen Delivers a Punch to Diffuse Large B-Cell Lymphoma Subtype
The combination of lenalidomide (Revlimid) and rituximab (Rituximab), dubbed the “R-squared” regimen, has gained attention lately, and ongoing trials are evaluating whether chemotherapy with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, prednisone) can be improved by adding a...
Expert Point of View: Eleni Efstathiou, MD, PhD
The magic of this research is that it requires a liquid biopsy [circulating tumor cells in the blood]—a simple blood collection,” said Eleni Efstathiou, MD, PhD, Associate Professor at The University of Texas MD Anderson Cancer Center, Houston, commenting on the study presented by Antonarakis and...
AR-V7 Predicts Resistance to Enzalutamide and Abiraterone in Men With Castration-Resistant Prostate Cancer
Androgen receptor (AR) splice variant 7 (V7) appears to be a new biomarker for response and disease progression in patients treated with enzalutamide (Xtandi) or abiraterone (Zytiga). The presence of AR-V7 in circulating tumor cells predicted resistance to both drugs in men with metastatic...
Expert Point of View: Martin Reck, MD, PhD
Martin Reck, MD, PhD, Head of Thoracic Oncology at the Hospital Grosshansdorf in Germany, discussed the anti–PD-1 abstracts at the ASCO Annual Meeting. “We have seen tremendous results for immunotherapies for the reactivation of the immune system in patients with advanced melanoma. The question...
Strong Showing for Anti–PD-1 Agents in Non–Small Cell Lung Cancer
Monoclonal antibodies targeting the programmed death receptor-1 (PD-1) pathway are expected to answer an unmet need in non–small cell lung cancer (NSCLC). With first-line platinum-doublets, 1-year overall survival is 30% to 50%, and while treatments targeting sensitizing mutations are more...
Long-Term Follow-up of Phase I Nivolumab Trial
In the longest follow-up to date of any programmed death (PD)-1 receptor inhibitor in previously treated advanced melanoma, one-third of patients are demonstrating durable responses to the investigational agent nivolumab, and in some cases, these persist following discontinuation of the drug,...
Ipilimumab Reduces Recurrences as Adjuvant Treatment of Melanoma
Ipilimumab (Yervoy) has transformed the treatment of metastatic melanoma, producing long-term responses in about 20% of patients. A phase III study has now evaluated its impact in the adjuvant setting, and the results are a bit less striking. Primary Endpoint The European Organisation for Research...
IOM Workshop Explores Growing Problems in Patient Access to Cancer Drugs
Cancer patients’ out-of-pocket costs are rising dramatically, and insurance premiums, cost sharing, and ancillary expenses can be devastating. Many people go bankrupt as a result of the high costs of health care. Drugs are among the most serious economic culprits. They grow more expensive every...
The More Things Change, the More They Stay the Same
The ASCO Annual Meeting in June confirmed—and expanded—the excitement of the oncology community about molecular medicine and its future. The complex molecular pathways were pictured in living color on many slides in many large auditoriums. Newspapers across the country were equally enthusiastic as...
Expert Point of View: Jeffrey S. Weber, MD, PhD
Jeffrey S. Weber, MD, PhD, Director of the Donald A. Adam Comprehensive Melanoma Research Center at the Moffitt Cancer Center and Research Institute in Tampa, Florida, formally discussed the prembrolizumab study at the ASCO Annual Meeting. He called the response rate and the ongoing responses...
'Impressive' Outcomes Achieved With Pembrolizumab in Advanced Melanoma
The latest bit of good news for the programmed death receptor-1 (PD-1)–targeting antibodies in advanced melanoma comes for pembrolizumab (MK-3475). While the results came from only a phase I study, they were among those chosen for presentation at an ASCO press briefing during the Annual Meeting....
High Response Rate and Good Safety Profile for Carfilzomib Plus Cyclophosphamide and Dexamethasone
A multicenter, open-label phase II trial found that the selective proteasome inhibitor carfilzomib (Kyprolis), in combination with cyclophosphamide and dexamethasone produced high complete response rates and was associated with low toxicity in patients with newly diagnosed multiple myeloma....
Colorectal Cancer Survivors Prefer More Information on Late Effects of Treatment and Recurrence Risks
Survivors of nonmetastatic colorectal cancer, when surveyed about their needs and preferences for survivorship information, responded that they would prefer receiving more information about late effects of treatment, challenges to expect, general health maintenance, and risks of recurrence. Most of ...
Women With Small, Node-Negative Breast Tumors Have Excellent Prognosis Without Chemotherapy
Women who have small (≤ 1 cm), node-negative breast tumors “have an excellent prognosis without chemotherapy,” concluded the authors of a prospective cohort study involving 4,113 women with T1a,b, N0, M0 breast cancer. “Size and tumor subtype may identify patients in whom the rate of recurrence...
International Leader in Urology, Professor John Fitzpatrick, Dies
His life was gentle, and the elements So mixed in him that Nature might stand up And say to all the world, “This was a man!” —William Shakespeare I have too many positive memories of John to regale you with here,” said Roger Kirby, MD, in a tribute to his close friend and colleague, John Michael...
Cancer Survivors Face Unique Challenges Reentering the Workforce
An online survey of 201 unemployed cancer survivors looking for work found that a majority—61%—are at least somewhat concerned that a potential employer would find out about their cancer diagnosis and not hire them. In this survey conducted by Cancer and Careers, 66% of participants said they...
Vaccine Targeting Tumor Antigen to Dendritic Cell Receptors Induces Antigen-Specific Immunity
Anticancer immunity may be enhanced by harnessing the ability of dendritic cells to initiate T-cell immunity through efficient uptake and presentation of endocytosed material. In preclinical models, delivery of tumor-associated antigens to dendritic cells using receptor-specific monoclonal...
EGFR Activation Increases Cancer Cell ‘Visibility’ for Cytotoxic T Lymphocytes
The antitumor activities of cytolytic T lymphocytes and natural killer cells are being increasingly investigated and exploited in cancer immunotherapy. One mechanism by which these cells recognize tumor cells is by engagement of NKG2D, an activating receptor on cytolytic T lymphocytes and natural...
High Macrophage Inhibitory Cytokine-1 Levels and Colorectal Cancer Risk
Chronic inflammation is implicated in the development of colorectal cancer, and the plasma inflammatory biomarker macrophage inhibitory cytokine-1 (MIC-1, GDF15) may have a direct role in tumorigenesis. As reported in Journal of the National Cancer Institute, Mehta and colleagues found that...
Moffitt Receives $1.6 Million Grant for Lung Cancer Screenings
Moffitt Cancer Center Thoracic Oncology Department Chair Scott Antonia, MD, PhD, received an Infrastructure Grant Florida’s James and Esther King Biomedical Research Program. The grant will help fund Moffitt’s comprehensive lung screening program. Earlier this year the U.S. Preventive Services Task ...
David C. Beyer, MD, FASTRO, Named President-Elect, ASTRO Board of Directors
Members of the American Society for Radiation Oncology (ASTRO) have elected David C. Beyer, MD, FASTRO, President-Elect of the ASTRO Board of Directors. Dr. Beyer will begin his term at the Annual Business Meeting in September during ASTRO’s 56th Annual Meeting in San Francisco. Colleen A.F....
Avoiding Antioxidant-Drug Interactions During Cancer Treatment
Many potential drug-nutrient interactions can affect cancer treatment. It is important to consider these interactions given the significant use of supplements and other self-treatment options during cancer care. Antioxidants account for a large portion of the $32 billion in supplement industry...
Patient Guides Available Through ASCO University Bookstore
ASCO Answers: Managing the Cost of Cancer Care explains the various costs associated with cancer treatment, including health-care coverage through the Affordable Care Act. It also provides a list of financial resources available to help offset expenses related to care and tips for organizing...
Coping With the Aftermath of Cancer
Editor’s note: In the July 10 issue of The ASCO Post, this article by Marie Krejci as told to Jo Cavallo was published; however, the published version was incomplete in that it did not reflect important updates made by Ms. Krejci. We apologize to Ms. Krejci for this error and to our readers for any ...
Do We Need So Much Emphasis on ‘Quality Care’?
Unfortunately, when I see The ASCO Post, my first impression is that you enable a group of researchers (part-time clinicians) to pontificate about their own agendas. The agenda that seems to be missing is the presentation of information that either supports or refutes the freight train of “quality...
Prostate Cancer Biomarkers: Improvement in Predicting Clinically Significant Disease
Prostate cancer will be diagnosed in 233,000 American men in 2014. It is one of the leading causes of death by a cancer (killing ~29,500 men annually).1 Hundreds of thousands of men undergo prostate biopsies each year, most for either benign disease or for a cancer that will never lead to their...
Surgical Biopsy Proves Safe for Selected Patients With Late-Stage Lung Cancer
Researchers at the University of California Davis have determined that surgical biopsies can be safely performed on select patients with late-stage non-small cell lung cancer, which should enhance their access to drugs that target specific genetic mutations such as epidermal growth factor receptor...
From Ireland to America and Back, Patrick G. Johnston, MD, PhD, Thrives on Bringing Research Findings to Clinical Practice
Patrick G. Johnston, MD, PhD, FMedSci, Professor of Oncology and President and Vice-Chancellor of Queen’s University Belfast, grew up in Derry, a city in Northern Ireland. Derry is distinct in being Ireland’s only remaining fully intact walled city, considered one of the finest examples of a walled ...
Focus on the Ohio Hematology Oncology Society
The Ohio Hematology Oncology Society (OHOS) was formed 2 decades ago to advocate for and provide educational seminars and networking opportunities to hematologists and medical oncologists throughout the states of Ohio and West Virginia. Today, the society is focused on the needs of its nearly 200...
How to Recognize and Manage Intertriginous Eruptions Related to Doxorubicin
Intertriginous areas refer to skin folds (such as axillae, inguinal creases, and inframammary creases), which are characterized by increased friction, temperature, and occlusion. Intertriginous drug reactions are an underrecognized side effect associated with pegylated liposomal doxorubicin...
Lung-MAP Trial Debuts—Other Personalized Studies Will Follow
Oncologists now have a means of bringing personalized medicine to advanced squamous cell carcinoma, and it involves a biomarker-driven clinical trial that maximizes the chance of successful treatment and new drug approvals. Lung-MAP (Lung Cancer Master Protocol) is a unique concept in which the...
The Road to Progress in Lung Cancer Treatment
Despite promising new agents and therapeutic approaches, 5-year lung cancer survival rates have lagged far behind those of most other malignancies. To shed light on some of the important issues facing lung cancer experts, The ASCO Post recently spoke with internationally recognized lung cancer...
Ongoing Clinical Trials Actively Recruiting Children With Cancer
The information in this Clinical Trials Resource Guide includes actively recruiting clinical studies of children with cancer. The studies include pilot and phase I and II studies evaluating new therapies, functional imaging tests, tests to measure the neuropsychological and behavioral function in...
